Company

Race Oncology Limited

Headquarters: Sydney, NSW, Australia

CEO: Mr. Phillip R. Lynch

ASX: RAC +5.15%

Market Cap

A$272.6 Million

AUD as of July 1, 2024

US$181.6 Million

Market Cap History

Race Oncology Limited market capitalization over time

Evolution of Race Oncology Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Race Oncology Limited

Detailed Description

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein for treating for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Race Oncology Limited has the following listings and related stock indices.


Stock: ASX: RAC wb_incandescent

Details

Headquarters:

Gateway, 1 Macquarie Place

Level 36

Sydney, NSW 2000

Australia

Phone: 61 3 9098 8750

Fax: 61 3 9098 8750